Rituximab as maintenance therapy for ANCA-associated vasculitides: pooled analysis and long-term outcome of 277 patients included in the MAINRITSAN trials

Conclusions
According to these results, it appears that the 84-month remission rate is higher with an 18-month fixed RTX regimen compared with AZA and 18-month tailored RTX. Also, extending RTX to 36 months does not appear to reduce the long-term relapse rate compared with the 18-month fixed RTX regimen. However, as this study was underpowered to make this comparison, further prospective studies are needed to determine the potential long-term benefits of extending treatment in these patients.

Source: Annals of the Rheumatic Diseases - January 11, 2024 Category: Rheumatology Authors: Delestre, F., Charles, P., Karras, A., Pagnoux, C., Neel, A., Cohen, P., Aumaitre, O., Faguer, S., Gobert, P., Maurier, F., Samson, M., Godmer, P., Bonnotte, B., Cottin, V., Hanrotel-Saliou, C., Le Gallou, T., Carron, P.-L., Desmurs-Clavel, H., Direz, G., Tags: Editor's choice, ARD Lay summaries, ARD, Vasculitis Source Type: research